Skip to search formSkip to main contentSkip to account menu

piragliatin

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Benzeneacetamides

Narrower (1)

RO4389620

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus: A systematic review
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… 
2016
2016
Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus
To evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD, glucose‐lowering effect) interaction between simvastatin… 
2016
2016
Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients
A glucokinase activator and a sulfonylurea might be coprescribed to synergize treatment success for type 2 diabetes (T2D). This… 
2014
2014
The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… 
2009
2009
Piragliatin, an allosteric activator of glucokinase, greatly enhances glucose-induced pancreatic islet respiration and insulin release.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)